Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Director's Remuneration and Consultancy agreement

28 Mar 2013 07:10

RNS Number : 0769B
Biome Technologies PLC
28 March 2013
 



28 March 2013

 

 

Biome Technologies plc

("Biome", "the Company" or "the Group")

 

Director's Remuneration and Consultancy Agreement

 

 

Biome Technologies plc announces that it has agreed with John Standen, Non Executive Chairman of the Company, a change to his remuneration arrangements.

 

From 1 March 2013 for a period of one year, Mr Standen's annual remuneration will reduce from the previous level of £38,250 to £18,000. All other terms and conditions of Mr Standen's contract of employment will remain unchanged.

 

This change is one of a number of measures the Company is undertaking in order to ensure that cash outgoings are minimised.

 

Biome also announces that it has entered into a consultancy agreement with Leapacross Ltd, a company of which John Standen is a director and the majority shareholder (the "Consultancy Agreement"). Under the terms of the Consultancy Agreement, Leapacross will provide strategic consultancy advice to the Company with regard to an assessment of the corporate strategy of Biome following the sale of the Biotec business and in light of the various growth paths available to the Company.

 

The Consultancy Agreement will be in place for the period commencing 2 April 2013 and will terminate no later than 31 October 2013. Payment for the services to be provided under the Consultancy Agreement will be a maximum of £28,000. This sum will be payable in three stages, being £8,000 on commencement of the Consultancy Agreement, £10,000 on 30 June 2013 and £10,000 on 31 October 2013, the latter two payments being subject to, inter alia, satisfactory performance of the Consultancy Agreement.

 

Biome and Leapacross Ltd have agreed that payments due under the Consultancy Agreement will be used to purchase ordinary shares in the Company at the prevailing market value from Channel House Trustees Limited as trustee of the Biome Technologies Plc Employee Benefit Trust as soon as reasonably practical after payment is due.

 

 

- Ends -

 

 

For further information please contact:

 

Biome Technologies plc

Tel: +44 (0) 2380 867 100

Paul Mines, Chief Executive Officer

www.biometechnologiesplc.com

 

Daniel Stewart & Company

Tel: +44 (0) 20 7776 6550

David Hart

www.danielstewart.co.uk

 

First Columbus

Tel: +44 (0) 20 3002 2070

Chris Crawford/Kelly Gardiner

www.first-columbus.com

 

FTI Consulting

Tel: +44 (0) 20 7831 3113

Oliver Winters/ Latika Shah

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZMGZFLNLGFZM
Date   Source Headline
21st Mar 20257:00 amRNSCancellation- Biome Technologies PLC
13th Mar 202512:22 pmRNSResult of GM & update on Cancellation
21st Feb 20257:00 amRNSProposed Cancellation & Notice of GM
18th Dec 20247:00 amRNSSecured Funding Facility
4th Dec 20247:00 amRNSTrading Update and Board Change
13th Nov 20247:00 amRNSTrading Update
25th Oct 20247:00 amRNSAppointment of Non-Executive Director
30th Sep 20245:00 pmRNSTotal Voting Rights
30th Sep 202411:08 amRNSContract win for Stanelco RF Division
20th Sep 20247:00 amRNSInterim Results
13th Sep 202410:58 amRNSHolding(s) in Company
12th Sep 202411:43 amRNSHolding(s) in Company
11th Sep 20243:01 pmRNSHolding(s) in Company
10th Sep 20247:00 amRNSHolding(s) in Company
9th Sep 20244:51 pmRNSHolding(s) in Company
4th Sep 20242:39 pmRNSResult of General Meeting and TVR
30th Aug 20245:00 pmRNSTotal Voting Rights
23rd Aug 20242:42 pmRNSHolding(s) in Company
22nd Aug 202411:00 amRNSHolding(s) in Company
22nd Aug 20247:00 amRNSResult of Retail Offer, Director dealing and TVR
21st Aug 20244:12 pmRNSHolding(s) in Company
21st Aug 20241:41 pmRNSHolding(s) in Company
16th Aug 20247:05 amRNSRetail offer to raise up to £80,000
16th Aug 20247:01 amRNSProposed Fundraise and other matters
16th Aug 20247:00 amRNSTrading update
10th Jul 20247:00 amRNSDirectorate Change
8th Jul 20247:00 amRNSTrading update
12th Jun 20247:00 amRNSGrant of Options
29th May 202410:57 amRNSResult of AGM, Interim CFO and Directorate Change
22nd May 20242:27 pmRNSContract win for Stanelco RF Division
15th May 20247:00 amRNSNotice of AGM and 2023 Annual Report
29th Apr 20247:01 amRNSTrading Update
29th Apr 20247:00 amRNSFinal Results 2023
15th Mar 20247:00 amRNSContract win for Stanelco RF Division
11th Mar 20241:59 pmRNSIssue of Convertible Loan Notes, PDMR Notification
15th Feb 20242:54 pmRNSContract win for RF Division
6th Feb 20247:00 amRNSTrading Update
13th Nov 20237:00 amRNSTrading Update
10th Oct 20234:32 pmRNSGrant of Options
27th Sep 20237:00 amRNSInterim Results
26th Jul 20237:00 amRNSTrading Update
30th Jun 20235:00 pmRNSTotal Voting Rights
22nd Jun 20237:00 amRNSContract win for Stanelco RF Division
31st May 20237:00 amRNSIssue of Equity, Director/PDMR Shareholding & TVR
25th May 20232:57 pmRNSAppointment of Non-Executive Director
25th May 202312:45 pmRNSResult of AGM
2nd May 20231:05 pmRNSDirector/PDMR Shareholding
27th Apr 20237:00 amRNSNotice of AGM and 2022 Annual Report
26th Apr 20237:01 amRNSTrading Update
26th Apr 20237:00 amRNSFinal Results 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.